New chemo listing in indolent Non-Hodgkin’s Lymphoma

A cancer medicine that doubles progression free survival in people with indolent Non-Hodgkin’s Lymphoma and is less toxic than previous chemotherapy regimens will be added to the Pharmaceutical Benefits Scheme on 1 May. Australian haematologists have welcomed the PBS listing of Ribomustin (bendamustine hydrochloride) for the first-line treatment of indolent Non-Hodgkin’s Lymphoma and Mantle Cell